
Sign up to save your podcasts
Or


What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?
Moderator: Ahmed Elsharkawy
Speakers: Ashley Brown, Tatyana Kushner and Sabela Lens
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
By European Association for the Study of the LiverWhat do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?
Moderator: Ahmed Elsharkawy
Speakers: Ashley Brown, Tatyana Kushner and Sabela Lens
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

7,689 Listeners

141 Listeners

321 Listeners

501 Listeners

70 Listeners

763 Listeners

7 Listeners

0 Listeners

131 Listeners

1,152 Listeners

193 Listeners

91 Listeners

517 Listeners

373 Listeners

0 Listeners